⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9943877 | 1.00 | — | — | |
| SCHEMBL3972493 | 1.00 | — | — | |
| SCHEMBL1311913 | 0.98 | — | — | |
| SCHEMBL9686981 | 0.86 | — | — | |
| SCHEMBL9686986 | 0.86 | — | — | |
| SCHEMBL29597368 | 0.84 | NAMPT (0.47) | — | |
| SCHEMBL14972809 | 0.84 | NAMPT (0.47) | — | |
| SCHEMBL28943338 | 0.84 | NAMPT (0.47) | — | |
| SCHEMBL979637 | 0.75 | — | — | |
| SCHEMBL3473156 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116945-A1 | EXATECAN-DERIVED TOPOISOMERASE-1 INHIBITORS PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-04-11 | — | — | US | disclosed |
| WO-2024054840-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | SIONNA THERAPEUTICS (US) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024049931-A1 | EXATECAN-DERIVED TOPOISOMERASE-1 INHIBITORS PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-03-07 | — | — | WO | disclosed |
| US-20190345130-A1 | SGC STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2019-11-14 | — | — | US | disclosed |
| EP-3159341-B1 | PYRIDINO[1,2-A]PYRIMIDONE ANALOGUE USED AS PI3K INHIBITOR | CHAI TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2019-08-21 | — | — | EP | disclosed |
| US-20190055204-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2019-02-21 | — | — | US | disclosed |
| US-10189809-B2 | SGC stimulators | IRONWOOD PHARMACEUTICALS, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-10077243-B2 | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2018-09-18 | — | — | US | disclosed |
| US-9856256-B2 | Pyridino[1,2-A]pyrimidone analogue used as P13K inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2018-01-02 | — | — | US | disclosed |
| US-20170305878-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-10-26 | — | — | US | disclosed |
| WO-2012003405-A1 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20100093691-A1 | TOPICAL FORMULATIONS | HELPERBY THERAPEUTICS LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| EP-2086542-A1 | TOPICAL FORMULATIONS | Helperby Therapeutics Limited (GB) | 2009-08-12 | — | — | EP | disclosed |
| US-20090137622-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LIMITED (GB) | 2009-05-28 | — | — | US | disclosed |
| WO-2009052191-A1 | INTERNALLY MASKED NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2009-04-23 | — | — | WO | disclosed |
| US-20090099253-A1 | Internally Masked Neopentyl Sulfonyl Ester Cyclization Release Prodrugs of Acamprosate, Compositions Thereof, and Methods of Use | XENOPORT, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| EP-1945211-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | Helperby Therapeutics Limited (GB) | 2008-07-23 | — | — | EP | disclosed |
| WO-2008056151-A1 | TOPICAL FORMULATIONS | HELPERBY THERAPEUTICS LIMITED (GB) | 2008-05-15 | — | — | WO | disclosed |
| WO-2007054693-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LIMITED (GB) | 2007-05-18 | — | — | WO | disclosed |